A phase II trial of cyclophosphamide and adriamycin in refractory squamous cell carcinoma of the head and neck
- 1 February 1985
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 8 (1) , 61-64
- https://doi.org/10.1097/00000421-198502000-00048
Abstract
A phase II trial of cyclophosphamide and adriamycin was carried out in 26 patients with recurrent squamous cell carcinoma of the head and neck, previously treated with cis-diamminedichloroplatinum-based regimens. The overall response rate was 46% (12/26 patients) with the median duration of response being 6.5 mo. Cyclophosphamide and adrimycin is an active combination in patients with previously treated squamous cell carcinoma of the head and neck.This publication has 3 references indexed in Scilit:
- Adjuvant chemotherapy with Cis-diamminodichloroplatinum II and 120-hour infusion 5-fluorouracil in stage III and IV squamous cell carcinoma of the head and neckCancer, 1983
- Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU-NSC 409462), and cyclophosphamide in refractory adenocarcinoma of the breast and other tumorsCancer, 1976
- SEQUENTIAL COMBINATION CHEMOTHERAPY FOR ADVANCED, RECURRENT, SQUAMOUS CARCINOMA OF HEAD AND NECK1976